Cargando...

Critical appraisal of bevacizumab in the treatment of ovarian cancer

Bevacizumab is the first molecular-targeted agent to be used for the treatment of ovarian cancer. Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial growth factor. Two randomized Phase III trials evaluated the combination of bevacizumab plus standard cytotoxic chemotherapy...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Drug Des Devel Ther
Main Authors: Yoshida, Hiroyuki, Yabuno, Akira, Fujiwara, Keiichi
Formato: Artigo
Idioma:Inglês
Publicado: Dove Medical Press 2015
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4423500/
https://ncbi.nlm.nih.gov/pubmed/25960638
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S83275
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!